Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

nhibitors; and the enabling capabilities of Cytokinetics biological focus. Such statements are based on management s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, that GSK or the NCI may decide to postpone or discontinue development efforts for GSK-923295 or ispinesib, respectively; that there may be difficulties or delays potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy, and Cytokinetics may not be able to obtain and maintain patent or trade secret protection for its intellectual property; that Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing if necessary; and that standards of care may change or others may introduce products or alternative therapies for the treatment of indications which Cytokinetics drug candidates and potential drug candidates currently or potentially target. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... EAST BRUNSWICK, N.J., Feb. 17, 2012  Savient Pharmaceuticals, Inc. (NASDAQ: ... Vice President and Chief Financial Officer of Savient will present ... February 28, 2012 at 8:30 AM Eastern Time.  The conference ... York City. A live webcast of the presentation ...
... (Nasdaq: ENDP ) today announced that Mark Gottlieb, ... the J.P. Morgan Annual Global High Yield & Leveraged Finance ... The conference will be held at the Loews Hotel in ... archive of the presentation will be available on the company,s ...
Cached Medicine Technology:Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 2
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... Air pollution could be putting patients with heart disease at ... , A study by the University of Edinburgh and Ume ... blood vessel function in men who have previously experienced a ... Heart Foundation and published in the New England Journal of ...
... Armed with satellite imagery, field samples, human Lyme disease ... from the University of New Hampshire, the New Hampshire ... sector will conduct work on the ecology and risk ... states in an effort to eventually identify "hot spots" ...
... Quilt a ,Beautiful Symbol, NEW YORK, Sept. 12 ... Bolds, as "a homemaker." Doing,everything the old-fashioned way, Aylene ... a clothes line, washing and drying her dishes,by hand, ... aroma from the kitchen met you at the front ...
... Where do personal,trainers go to gain more knowledge? Well, ... sciences relating to fitness from conferences, trade,associations and certifying ... list. PersonalTrainerTV.com is a new membership web site for,fitness ... from leading,experts in the industry. According to its ...
... 2007 Approximately 30% of Canadians suffer daily from ... the intensity, but all chronic pain is debilitating and ... Lamb, a clinician nurse at the Pain Centre of ... Shir, the Director of the Centre, shows that methadone ...
... PORTLAND, Maine, Sept. 12 JHA has released the ... Survey. This leading,benchmarking survey reports group Long Term Disability ... premium results for the first,half of the year. The ... of the top twenty carriers, as ranked by inforce ...
Cached Medicine News:Health News:Diesel exhaust may increase risk in patients with heart disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 3Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 4Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 2Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 3Health News:Methadone and systematic follow-up: the best solution for managing chronic pain 2Health News:JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: